Immutep Limited (IMMP) Nasdaq

No ho capito a che ora espongono i dati. O non hanno indicato il fuso o sono fuso io che non lo vedo.
 
https://app.sharelinktechnologies.com/announcement/asx/f988c1e15601a8fa056e52c10ade13d2

ASX/Media Release Immutep Announces Positive Final Data in 2 nd Line Metastatic NSCLC Patients Refractory to Anti-PD-(L)1 Therapy at European Lung Cancer Congress 2023 • Efti plus pembrolizumab achieved mOS of 9.9 months and a 39% OS rate at 21 months, which compare favourably to typical 6-9 months mOS and a 10-15% OS rate for standard-of-care chemotherapy • 83% of patients studied for Tumour Growth Kinetics showed deceleration of tumour growth or shrinkage of tumours, previously increasing under PD-(L)1 monotherapy or in combination with chemotherapy • ORR of 8.3%, DCR of 33.3%, and 6-month PFS rate of 25% in all-comer PD-L1 patient population, with most of these PD-X refractory patients (75%) having negative or low PD-L1 expression • ORR of 33.3%, 6-month PFS of 50%, and mOS not yet reached for patients with high PD-L1 expression • Combination of efti plus pembrolizumab well tolerated in this difficult-to-treat patient population without any new safety signals SYDNEY, AUSTRALIA – 31 March 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company developing novel LAG-3 immunotherapiesfor cancer and autoimmune disease, today announces positive final data from Part B of the TACTI-002 Phase II trial in 2 nd line metastatic non-small cell lung cancer (NSCLC) patients refractory to anti-PD-(L)1 therapy via a Mini Oral presentation at ESMO’s European Lung Cancer Congress (ELCC) 2023. The presentation by Margarita Majem, M.D., Ph.D., Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, titled “Final data from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3) & pembrolizumab 2nd line metastatic NSCLC patients resistant to PD-1/PD-L1 inhibitors” discusses how eftilagimod alpha, a soluble LAG-3 protein, targets a subset of MHC class II molecules found on antigenpresenting cells (e.g., dendritic cells, monocytes) to mediate their activation and subsequent CD8+ T cell activation/proliferation. This unique stimulation of antigen-presenting cells (APC) leads to a broad antitumour immune response, and the addition of efti to pembrolizumab may help refractory 2 nd line NSCLC patients that have few therapeutic options by reverting their anti-PD-(L)1 resistance. Dr. Majem stated, “In this difficult-to-treat patient population, these clinical results beneficially show that subcutaneous administration of eftilagimod alpha in combination with pembrolizumab is safely stimulating a broad immune response that may revert resistance to anti-PD-X therapy. The data supports further clinical investigation of eftilagimod alpha in combination with pembrolizumab for patients with anti-PD-(L)1 refractory non-small cell lung cancer that have limited treatment options.” All patients (N=36) had confirmed progression (e.g., two consecutive scans) after standard-of-care 1st line treatment with anti-PD-X therapy, including 67% that received anti-PD-X therapy and chemotherapy (72% when excluding non-evaluable patients). In these PD-X refractory, 2L metastatic NSCLC patients, the chemofree combination of efti plus pembrolizumab achieved a median Overall Survival (mOS) of 9.9 months and a 39% OS rate at 21 months, which compare favourably to typical 6-9 months mOS and a 10-15% OS rate at 21 months for standard-of-care chemotherapy. Additionally, Tumour Growth Kinetics (TGK) analysis looking at the difference of the sum of the largest diameters of target lesions in the pre- and post-baseline setting was performed on patients with data available on the same lesions from prior failed therapy and post-baseline (N=24). 83.3% of patients showed shrinkage (33%) or deceleration of tumour growth (50%). Notably, 36%, 39%, and 16.7% of patients had a PD-L1 Tumour Proportion Score (TPS) of <1%, 1-49%, and >50%, respectively, and 8.3% of patients were not evaluable for PD-L1 expression. Efti plus pembrolizumab had an ORR of 8.3%, a DCR of 33%, and a 6-month PFS rate of 25% in the all-comer PD-L1 patient population, with most of these PD-X refractory patients (75%) having negative or low PD-L1 expression. The ORR, PFS, and OS were more pronounced in patients with high PD-L1 expression (N=6) or who were secondary resistant (N=25). For patients with ≥50% PD-L1 TPS expression, mOS was not yet reached, ORR was 33.3%, and 6-month PFS was 50%. Efti plus pembrolizumab was well tolerated without any new safety signals, and there was no treatment discontinuation due to adverse reactions. Immutep CSO and CMO, Dr Frederic Triebel, noted: “The maturation of data across all three indications in the all-comer TACTI-002 trial, namely 1st line non-small cell lung cancer, 2nd line head and neck cancer, and 2nd line PD-X refractory non-small cell lung cancer, has continued to strengthen our belief that combining immunotherapies that harness the power of both innate and adaptive immunity may be very effective in fighting cancer. Efti’s unique targeting and activation of antigen-presenting cells has shown a promising benefit with checkpoint inhibitors that target T cells, and we believe the combination of efti and pembrolizumab has significant potential to safely improve outcomes for cancer patients.” Immutep CEO, Marc Voigt, concluded, “These encouraging results and overall survival trends in patients refractory to PD-1/PD-L1 containing therapy, which have confirmed progression via two consecutive scans, offers a potential therapeutic pathway for many in dire need of new options. As we assess this potential, we continue to focus our late-stage clinical development of efti in combination with anti-PD-1 therapy in 1st line non-small cell lung cancer and 1st line head and neck cancer and look forward to providing more details on both as the year progresses.” The Mini Oral presentation will be available on the Posters & Publications section of Immutep’s website.
 
che è sta roba ?
se non sbaglio BNYMC è l'intermediario che gestisce ADR immp in USA
credo che questo documento segnali semplicemente che le stock immp disponibili sul nasdaq sono passate da 235 milioni e rotti a 220 milioni e rotti (quindi da 23,5 milioni a 22 milioni circa)

spero di aver reso l'idea...
 
Qualcuno che compra nel pre c'è...
 
Al momento sembrerebbe una singola persona con quote un minimo significative.
 
Mi sarei aspettato una giornatina con almeno 500/600k di volume,se non più. I dati mi son parsi buoni,niente di sorprendente ma buoni.
non è un buon periodo le le bio,che si trascina da molti mesi ormai.
Non c’è news che tenga,il Sentiment è totalmente bearish.
ogni tanto qualcuna fa il botto con un +100% ma solo dopo una lunga discesa da brividi.
tutto sommato immp ha tenuto abbastanza bene nell’ultimo anno.
anche oggi è stata affossata con pochi spicci,e questo fa ben sperare. Se avessero osato con i volumi passati a tratti oggi potevano affossarla a -10 o anche più.
non credo sia ancora finita anche perche adesso non ci sarà nemmeno l’attesa di un catalizzatore nel breve ed hanno gioco facile.
questa lateralizzaziine ribassista permarrà fino a fine estate,imho,poi vedremo se ci sarà un colpo di reni prima del tax selling,in prossimità di nuovi dati.
 
In Australia un bel candelone rosso da quasi -8%
 
In Australia un bel candelone rosso da quasi -8%
Caspiterina che legnata :shit: Mi sa che sono stato l’unico ad aver pensato i dati positivi.
edmho anche mediati:wall: mi sa che non ci ho capito molto dello stock e siamo rimasti un po’ tutti con il cerino in mano:'(
 
Voi pensate di resistere o avete già venduto?
 
In Australia un bel candelone rosso da quasi -8%
nel Pre in AMerica sta facendo +8% non capisco, c'è qualcunio che ha comprato a 1,98 (+18%) :rolleyes:

Ora Pre-Mercato (ET)Prezzo Pre-MercatoVolume Delle Azioni Pre-Mercato
06:44:48$1.981,000
06:44:18$1.98500
06:44:13$1.98100
06:44:09$1.981,000
06:43:56$1.98100
06:43:44$1.98200
06:43:39$1.981,000
06:43:23$1.98200
06:43:15$1.98400
06:43:14$1.987,000
06:43:11$1.98500
06:43:06$1.98100
06:42:00$1.98150
06:40:36$1.8620
06:40:36$1.86168
06:40:36$1.8220
06:40:36$1.81168
06:40:35$1.82100
06:40:35$1.82100
06:40:35$1.76100
 
Non li ho mica capiti nemmeno io quegli acquisti, magari pensavano potesse partire oggi per qualche motivo. Poveri sprovveduti che non conoscono ancora Immutep
 

goetzpartners securities - Potential standard of care in lung and other cancers

 

Allegati

  • a.pdf
    339,9 KB · Visite: 11
Indietro